Xuebijing Injection Study Highlighted at ATS 2024, Showcasing TCM's Potential in
2024-06-17 15:05:10
Return to listSan Diego, CA – 20 May 2024: The American Thoracic Society (ATS) annual meeting, one of the most influential conferences in the respiratory field, was recently held in San Diego, USA. This prestigious event provided a platform for nearly ten thousand global scholars and participants to present and discuss the latest advancements in respiratory medicine. Among the highlights was a study on Xuebijing Injection, a core product of Tianjin Chase Sun Pharmaceuticals (Chase Sun Pharma), demonstrating the increasing recognition of traditional Chinese medicine (TCM) in the global medical community.
The study, which focused on the efficacy of Xuebijing Injection in treating sepsis, was cited as a key example during the annual review of cutting-edge developments in respiratory medicine. This recognition by ATS underscores the academic value and potential of TCM in addressing critical health issues. The randomized controlled clinical trial showed that Xuebijing significantly reduced the 28-day all-cause mortality rate by 7.3% in sepsis patients, offering new hope for treating this severe condition.
The research findings were published in the esteemed medical journal **JAMA Internal Medicine**, drawing widespread attention and acclaim. Notably, no other drug has been proven effective in improving sepsis prognosis globally, marking this study as a groundbreaking achievement in medical research and a significant step for TCM on the international stage.
The success of Xuebijing is the result of years of dedicated research by Chase Sun Pharma. Since its approval as a Category II new drug in 2004, the company has continuously invested in its development. In 2010, Chase Sun Pharma launched an evidence-based research program for Xuebijing, encompassing multiple disciplines such as respiratory, emergency, and critical care medicine. This decade-long research initiative has enriched the clinical efficacy and safety evidence base, transforming these findings into clinical practice guidelines and expert consensus recommendations.
The ATS annual meeting, renowned for focusing on academic hotspots and converging on cutting-edge advancements, provided an ideal venue for presenting Xuebijing's research outcomes. The attention and recognition it received at this high-profile event attest to its academic value and innovative potential.
Chase Sun Pharma's commitment to research and development has been a cornerstone of its success. The company's substantial investment in R&D has not only yielded significant advancements in drug development but also accelerated the translation of scientific findings into practical healthcare solutions. As a result, Chase Sun Pharma has secured a prominent position in the competitive landscape of new drug development, continually enhancing its capabilities in research innovation.
